Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Urticaria therapeutics.

Synopsis

• In 2022, there will be more than 80 million diagnosed prevalent cases of urticaria across 16 pharmaceutical markets.
• Most of the leading marketed drugs for urticaria are second-generation H1-antihistamines, which are used as the first-line symptomatic treatment for the disease.
• Out of 50 drugs in urticaria pipeline, more than 20 molecules are currently in mid- to late-stage development.
• Among industry-sponsored trials, Novartis has sponsored the highest number of trials in urticaria over the past 10 years, followed by Genentech.
• Acquisitions accounted for over 35% of all deals in each of the regions except in South America and Africa, where licensing agreements are predominant.
• Within the next 30 months, regulatory filing for only one drug within urticaria space is expected.

Scope

GlobalData’s Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Urticaria market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Urticaria market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.